AR-V7 — SCE Medical Oncology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: C — AR-V7 confers resistance to enzalutamide and abiraterone
AR-V7 is a constitutively active androgen receptor splice variant lacking the ligand-binding domain, rendering it insensitive to enzalutamide (AR antagonist) and abiraterone (CYP17 inhibitor). Antonarakis et al (NEJM 2014) showed that AR-V7-positive patients had no PSA response to enzalutamide/abiraterone but maintained taxane sensitivity. AR-V7 CTC testing is available clinically and may guide treatment sequencing in mCRPC, particularly regarding ARPI vs taxane choice after prior ARPI failure.
Reference: https://www.nice.org.uk/guidance/conditions-and-diseases/cancer